Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 767Lymphoma 713Leukemia, Lymphocytic, Chronic, B-Cell 560Lymphoma, Follicular 515Lymphoma, Large B-Cell, Diffuse 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Recurrence 317Lymphoma, B-Cell 294Neoplasms 261Lymphoma, Mantle-Cell 251Leukemia 231Multiple Myeloma 189Hodgkin Disease 179Leukemia, Myeloid, Acute 178Lymphoma, B-Cell, Marginal Zone 135Lymphoma, T-Cell, Peripheral 119Burkitt Lymphoma 105Myelodysplastic Syndromes 101Hematologic Neoplasms 100Lymphoma, T-Cell, Cutaneous 88Waldenstrom Macroglobulinemia 84Leukemia, B-Cell 79Lymphoma, T-Cell 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Lymphoproliferative Disorders 57Hematologic Diseases 57Melanoma 54Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 51Mycosis Fungoides 49

Interventions

midostaurin 1glofitamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Aggression × Lymphoid × Clear all
NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting
178 enrolled
Lymphoid

Aggression, Lymphoma, Non-Hodgkin, Recurrence

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡